Cargando…

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains most...

Descripción completa

Detalles Bibliográficos
Autores principales: Kachmazov, Andrei, Bolotina, Larisa, Kornietskaya, Anna, Kuznetsova, Olesya, Ivanov, Maxim, Fedenko, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478540/
https://www.ncbi.nlm.nih.gov/pubmed/36119518
http://dx.doi.org/10.3389/fonc.2022.953908
_version_ 1784790596183916544
author Kachmazov, Andrei
Bolotina, Larisa
Kornietskaya, Anna
Kuznetsova, Olesya
Ivanov, Maxim
Fedenko, Alexander
author_facet Kachmazov, Andrei
Bolotina, Larisa
Kornietskaya, Anna
Kuznetsova, Olesya
Ivanov, Maxim
Fedenko, Alexander
author_sort Kachmazov, Andrei
collection PubMed
description PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains mostly undetermined. Here we report a clinical case of a 56-year-old woman with pancreatic ductal adenocarcinoma harboring a somatic PALB2 mutation. Following disease progression after 10 cycles of FOLFIRINOX chemotherapy and two cycles of second-line gemcitabine, she was switched to talazoparib and achieved a complete clinical response after 25 months of treatment. The patient remains alive without clinical or radiological signs of disease progression three years after the start of talazoparib with no targeted therapy-related toxicities. This case highlights the role of broad molecular profiling as a window of opportunity to achieve a durable response for selected pancreatic cancer patients while pinpointing our gaps in understanding the whole picture of management of these patients since a new puzzle element represented by PARP inhibitors was introduced to clinical practice.
format Online
Article
Text
id pubmed-9478540
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94785402022-09-17 Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review Kachmazov, Andrei Bolotina, Larisa Kornietskaya, Anna Kuznetsova, Olesya Ivanov, Maxim Fedenko, Alexander Front Oncol Oncology PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains mostly undetermined. Here we report a clinical case of a 56-year-old woman with pancreatic ductal adenocarcinoma harboring a somatic PALB2 mutation. Following disease progression after 10 cycles of FOLFIRINOX chemotherapy and two cycles of second-line gemcitabine, she was switched to talazoparib and achieved a complete clinical response after 25 months of treatment. The patient remains alive without clinical or radiological signs of disease progression three years after the start of talazoparib with no targeted therapy-related toxicities. This case highlights the role of broad molecular profiling as a window of opportunity to achieve a durable response for selected pancreatic cancer patients while pinpointing our gaps in understanding the whole picture of management of these patients since a new puzzle element represented by PARP inhibitors was introduced to clinical practice. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9478540/ /pubmed/36119518 http://dx.doi.org/10.3389/fonc.2022.953908 Text en Copyright © 2022 Kachmazov, Bolotina, Kornietskaya, Kuznetsova, Ivanov and Fedenko https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kachmazov, Andrei
Bolotina, Larisa
Kornietskaya, Anna
Kuznetsova, Olesya
Ivanov, Maxim
Fedenko, Alexander
Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
title Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
title_full Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
title_fullStr Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
title_full_unstemmed Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
title_short Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
title_sort complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic palb2 mutation: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478540/
https://www.ncbi.nlm.nih.gov/pubmed/36119518
http://dx.doi.org/10.3389/fonc.2022.953908
work_keys_str_mv AT kachmazovandrei completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview
AT bolotinalarisa completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview
AT kornietskayaanna completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview
AT kuznetsovaolesya completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview
AT ivanovmaxim completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview
AT fedenkoalexander completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview